<DOC>
	<DOCNO>NCT01660035</DOCNO>
	<brief_summary>The purpose REVERSE Post Approval Study ( PAS ) confirm benefit observed REVERSE RAFT pivotal study `` real-world '' clinical practice .</brief_summary>
	<brief_title>The Product Surveillance Registry REVERSE Post Approval Study</brief_title>
	<detailed_description>The REVERSE PAS estimate 3-year survival probability freedom heart failure hospitalization heart failure event patient implant Medtronic CRT-D device meet expand indication criterion QRS duration ≤ 150 m .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient legally authorize representative provide write authorization and/or consent per institution geographical requirement Patient intend receive treat Medtronic CRTD meet expand CRTD indication criterion QRS ≤ 150ms Patient within 30 day implant Patient , , inaccessible followup Patient exclusion criterion require local law Patient currently enrol plan enroll concurrent drug and/or device study may confound result</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>